Alivus Life Sciences Acquires Controlling 65.01% Stake in IQGEN-X Pharma
Alivus Life Sciences Ltd 路 Others (Uncategorized) 路 11 Nov 2026, 11:58 pm
Alivus Life Sciences Acquires Controlling 65.01% Stake in IQGEN-X Pharma Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has initiated the closing of its Share Purchase Agreement to acquire a 76% stake in IQGEN-X Pharma Private Limited. As of 11th Nov'26, the company acquired 7,36,096 equity shares, representing a 65.01% paid-up equity stake, making IQGEN-X a subsidiary. The remaining stake up to 76% will be acquired in due course.
Original exchange filing (PDF)
More announcements from Alivus Life Sciences Ltd
- Please find enclosed herewith disclosure under Regulation 30 of SEBI(LODR), 2015. 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nirma Ltd 路 07 Nov 2026
- Please find attached herewith submission with respect to transcript of the earning call. 路 06 Nov 2026
- Please find enclosed herewith intimation for Analyst/Investor meeting. 路 04 Nov 2026
- Please find enclosed herewith intimation for Analyst/Investor Meet. 路 30 Oct 2026
- We hereby confirm that we have uploaded audio recording of the Q2 FY2027 Earnings Call held on October 30, 2026 on the website of the Company. 路 30 Oct 2026
- Please find enclosed herewith intimation with respect to allotment of equity shares under "Employee Stock Option Scheme, 2021" 路 30 Oct 2026
- Please find enclosed herewith Investor Presentation for Q2 FY26-27. 路 30 Oct 2026
